Home Pharmaceutical global-stroke-market

Pharmaceutical

Image

Global Stroke Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • Nov 2023
  • Global
  • 350 Pages
  • No of Tables: 1489
  • No of Figures: 44

Global Stroke Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 30308643.28 Thousand
Diagram Market Size (Forecast Year) USD 52232195.85 Thousand
Diagram CAGR %

Global Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Treatment (Medication, Surgery, and Other Therapy), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Gender (Female and Male), End User (Hospitals & Clinics, Specilaty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct, Retail and Online) – Industry Trends and Forecast to 2030.

  

Stroke Market Analysis and Insights

Stroke is a significant global health concern with thousands of people affected every year and a substantial economic burden on healthcare systems worldwide. The global stroke market includes a wide range of stakeholders, from pharmaceutical companies developing medications for stroke prevention and treatment, medical device manufacturers producing tools for diagnosis and intervention, to rehabilitation and care providers focusing on post-stroke recovery, However, the market faces challenges such as the high cost associated with treatment cost, lack of skilled personnel, and complex regulatory requirements .

Stroke MarketStroke Market

The global stroke market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.5% in the forecast period of 2023 to 2030 and is expected to reach USD 52,232,195.85 thousand by 2030 from USD 30,308,643.28 thousand in 2022.

Global stroke market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Thousand

Segments Covered

Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Treatment (Medication, Surgery, and Other Therapy), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Gender (Female and Male), End User (Hospitals & Clinics, Specilaty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct, Retail and Online)

Countries Covered

U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East and Africa

Market Players Covered

Bayer AG, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Medtronic, Teva Pharmaceuticals USA, Inc., Pfizer Inc., AstraZeneca, Viatris Inc., Lupin, Abbott, DAIICHI SANKYO COMPANY, LIMITED, Penumbra, Inc., Oxford Laboratories Pvt. Ltd., Sandoz Group AG (Subsidiary of Novartis AG), GLENMARK PHARMACEUTICALS LTD., Fresenius SE & Co. KGaA, and Amneal Pharmaceuticals LLC, among others.

Market Definition

A stroke, encompassing both cardiovascular and brain strokes, is a sudden and severe disruption of blood flow within the circulatory system that results in damage to brain tissue or other vital organs. This interruption in blood supply may be caused by either the blockage of blood vessels (ischemic stroke) or the rupture of blood vessels (haemorrhagic stroke).

Global Stroke Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

  • Rising Incidences of Stroke

In recent years, the world has witnessed a notable surge in the prevalence of stroke, emerging as a significant global health concern. While the incidence of strokes varies by region and is influenced by factors such as age, lifestyle, and healthcare access, the overall trend is one of increasing prevalence.

For instance

•          In May 2023, according to the article published by eClinical Medicine, stroke is the second leading cause of death and the third leading cause of disability worldwide. Over the past 30 years, there has been an increase in the absolute number of incidents (70%) and prevalent (85%) strokes, and deaths (43%) from stroke. The increasing use of stroke in genetic studies reflects their unique advantages in the field of genetic research.

In conclusion, factors such as the aging population, unhealthy lifestyles, and increased prevalence of risk factors, all contribute to the growing number of stroke cases. Thus, the rising incidence of stroke is expected to drive market growth.

  • Increasing Number of Patients with Hypertension and Coronary Heart Diseases

Hypertension, commonly known as high blood pressure, is a medical condition characterized by elevated force of blood against the walls of arteries. Coronary heart disease also known as coronary artery disease, results from the gradual accumulation of fatty deposits (atherosclerosis) in the coronary arteries, which supply oxygen and nutrients to the heart muscle.

Stroke is intimately connected to the increasing prevalence of hypertension and coronary heart disease (CHD) patients due to shared risk factors and underlying physiological mechanisms. Hypertension, or high blood pressure, significantly raises the risk of stroke by damaging blood vessels and increasing the likelihood of blood clots. Prolonged hypertension can lead to atherosclerosis, and accumulation of fatty deposits in arteries. This can result in narrowed blood vessels and reduced blood flow to the brain, increasing the risk of both ischemic (caused by blockages) and hemorrhagic (caused by bleeding) strokes. High blood pressure can also damage the blood vessels in the brain, making them more prone to rupture or blockage, further escalating the stroke risk.

Stroke Market

Opportunity

  • Expansion of Telemedicine and Remote Monitoring

The expansion of telemedicine and remote monitoring has been a significant development in stroke treatment and care. These technologies offer numerous advantages, including increased accessibility, rapid assessment, and continuous monitoring, which can significantly improve stroke patients' management and outcomes.

Telemedicine enables patients to have real-time video consultations with healthcare providers, particularly stroke specialists. In the event of a stroke, time is of the essence, and telemedicine allows for immediate assessment and decision-making, reducing delays in treatment. Telemedicine also extends stroke care to underserved and rural areas, where access to stroke specialists may be limited..

These technologies enhance access to specialized stroke care, offer rapid diagnosis helps in making treatment protocol, and facilitate ongoing monitoring and rehabilitation. As a result, healthcare providers can reach a broader patient base, particularly in underserved and remote areas, while streamlining care coordination through stroke networks. The timely provision of stroke expertise and decision support in thrombolytic therapy can improve patient outcomes and reduce the risk of long-term disabilities

Restraint/ Challenge

  • High Cost Associated with Treatment of Stroke

The high cost associated with the treatment of stroke is a significant concern in healthcare, impacting both individuals and healthcare systems.

The initial stage of stroke treatment involves emergency medical care, including ambulance services, emergency room evaluations, and diagnostic tests such as CT scans and MRIs. The urgency and complexity of this care drive up costs.

For instance,

  • In July 2020, according to an article published by Brand New Vegan LLC, strokes constitute different tests which includes multiple CT scans, an MRI, a slew of other assorted tests and labs, and a semi-private room overnight for further observation, which is estimated a USD 24,000 per person in the U.S.

Complications in Managing Stroke in Patients with Multiple Chronic Conditions

Managing stroke in patients with multiple chronic conditions presents complex challenges, as these coexisting health issues can complicate treatment and recovery.

One of the complications in managing stroke in patients with multiple chronic conditions are;

Polypharmacy and Medication Interactions: Patients with multiple chronic conditions often take multiple medications, which can lead to polypharmacy, increasing the risk of drug interactions and adverse effects. In stroke management, this can complicate medication decisions, especially for anticoagulants or antiplatelet drugs, and make it challenging to balance the risk of bleeding and clotting.

Recent Developments

  • In May 2023, Bristol Myers Squibb (NYSE: BMY) in partnership with Janssen Pharmaceuticals, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson (Janssen), announced that all three potential indications for milvexian, an investigational oral factor XIa (FXIa) inhibitorhas now received fast track designation from the U.S. Food and Drug Administration (FDA). The names include all three trials seeking indications in the Phase 3 Librexiadevelopment program (Librexia STROKE, Librexia ACS, and Librexia AF), all dosed patients. The Librexia program is unparalleled as a comprehensive clinical development program for FXIa, providing extensive data from nearly 50,000 patients. This opens the door to a whole new range of currently neglected patients due to the risk of bleeding.
  • In January 2023, Penumbra, Inc., a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA) approval and launch of Lightning Flash, the most advanced and powerful mechanical thrombectomy system on the market. Lightning Flash features Penumbra's new Lightning Intelligent Aspiration technology, which now has two clot detection algorithms. Combined with innovative catheter technology, the Lightning Flash is designed to quickly remove large blood clots from the body, including venous embolism and pulmonary embolism (PE). This launch will help the company expand its product portfolio because the advanced results of this new technology are exceptionally traceable, and it has the unique ability to differentiate flowing blood from clots.
  • In July 2023, Roche announced a new partnership with Alnylam to develop and commercialize zilebesir, an investigational RNAi therapy currently in Phase 2 for treating high blood pressure. This collaboration combines Alnylam's proven experience in RNAi therapy with Roche's global commercial reach, commitment to innovation, and desire to change the landscape for patients with severe cardiovascular disease.
  • In February 2021, Sanofi’s Plavix (clopidogrel) got approval by the European Commission for its use in combination with aspirin in adult patients with moderate or high-risk transient ischemic attack (TIA) (ABCD2 score ≥4) or mild ischemic stroke (IS). Twenty-four hours of a TIA or IS event. In this new indication, use can be continued for 21 days, followed by long-term single antiplatelet therapy. The additional indication is based on the results of a two-investigator-initiated, double-blind, randomized, placebo-controlled phase 3 study involving more than 10,000 patients. Studies have shown that the combination of clopidogrel and aspirin started within 24 hours is better than aspirin in reducing the risk of subsequent stroke and has a generally acceptable safety profile. This new approval demonstrates companies unwavering commitment to advancing cardiovascular care.
  • In September 2020, Daiichi Sankyo Company Limited announced that it had submitted a supplemental application in Japan for the extended approval of the anticoagulant edoxaban (edoxaban benzoate hydrate) in elderly patients with nonvalvular regurgitation and severe bleeding risk. This application is based on the results of a Japanese Phase 3 clinical trial (ELDERCARE-AF trial) in 984 patients with non-valvular atrial fibrillation who are at least 80 years old and have a high risk of bleeding and are not suitable for other available anticoagulant therapies. Daiichi Sankyo plans to contribute to treating elderly patients with non-valvular atrial fibrillation by offering a new treatment option.

Global Stroke Market Scope

Global stroke market is categorized into five notable segments based on type, treatment, diagnosis, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Ischemic Stroke
  • Hemorrhagic Stroke
  • Transient Ischemic Attack (TIA)

On the basis of type, the global stroke market is segmented into ischemic stroke, hemorrhagic stroke, and Transient Ischemic Attack (TIA).

Treatment

  • Medication
  • Surgery
  • Others Therapy

On the basis of treatment, the global stroke market is segmented into medication, surgery, and others therapy.

Diagnosis

  • Imaging Test
  • Blood Test
  • Echocardiogram
  • Lumbar Puncture
  • Others

On the basis of diagnosis, the global stroke market is segmented into imaging test, blood test, echocardiogram, lumbar puncture, and others.

Gender

  • Female
  • Male

On the basis of gender, the global stroke market is segmented into female and male.

End User

  • Hospitals & Clinics
  • Specialty Clinics
  • Ambulatory Surgical Center
  • Homecare
  • Laboratories
  • Others

On the basis of end-user, the global stroke market is segmented into hospitals & clinics, specialty clinics, ambulatory surgical center, homecare, laboratories, and others.

Distribution Channel

  • Direct
  • Retail
  • Online

On the basis of distribution channel, the global stroke market is segmented into direct, retail, and online.

Stroke Market

Global Stroke Market Regional Analysis/Insights

The global stroke market is categorized into six notable segments such as type, treatment, diagnosis, gender, end user, and distribution channel.

The countries covered in this market report U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East and Africa.

North America is expected to dominate the market due to the presence of key market players in the largest consumer market with high GDP. The U.S. dominates North America region due to the rise in technological advancement in the stroke products market. The Germany is expected to dominate the Europe region due to the strong presence of key players. China is expected to dominate the Asia-Pacific region due to the rising incidences of stroke and increasing demand from emerging markets and expansion.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Stroke Market

Competitive Landscape and Global Stroke Market Share Analysis

The global stroke market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the global stroke market.

Some of the major players operating in the global stroke market are Bayer AG, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Medtronic, Teva Pharmaceuticals USA, Inc., Pfizer Inc., AstraZeneca, Viatris Inc., Lupin, Abbott, DAIICHI SANKYO COMPANY, LIMITED, Penumbra, Inc., Oxford Laboratories Pvt. Ltd., Sandoz Group AG (Subsidiary of Novartis AG), GLENMARK PHARMACEUTICALS LTD., Fresenius SE & Co. KGaA, and Amneal Pharmaceuticals LLC, among others.

SKU-

TABLE 1 GLOBAL STROKE MARKET, BY TYPE, 2022-2030 (USD THOUSAND)

TABLE 2 GLOBAL ISCHEMIC STROKE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 GLOBAL ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 4 GLOBAL HEMORRHAGIC STROKE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 GLOBAL HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 6 GLOBAL TRANSIENT ISCHEMIC ATTACK (TIA) IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 7 GLOBAL STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 8 GLOBAL MEDICATION IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 9 GLOBAL MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 10 GLOBAL BLOOD PRESSURE MEDICINES IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 11 GLOBAL ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 12 GLOBAL DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 13 GLOBAL CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 14 GLOBAL BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 15 GLOBAL ALPHA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 16 GLOBAL ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 17 GLOBAL ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 18 GLOBAL TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 19 GLOBAL STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 20 GLOBAL SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 21 GLOBAL MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 22 GLOBAL BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 23 GLOBAL MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 24 GLOBAL ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 25 GLOBAL PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 26 GLOBAL MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 27 GLOBAL MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 28 GLOBAL SURGERY IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 29 GLOBAL SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 30 GLOBAL OTHER THERAPY IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 GLOBAL OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 32 GLOBAL STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 33 GLOBAL IMAGING TEST IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 34 GLOBAL IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 35 GLOBAL BLOOD TEST IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 GLOBAL ECHOCARDIOGRAM IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 37 GLOBAL LUMBAR PUNCTURE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 GLOBAL OTHERS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 GLOBAL STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 40 GLOBAL FEMALE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 GLOBAL MALE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 GLOBAL STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 43 GLOBAL HOSPITALS & CLINICS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 44 GLOBAL SPECIALTY CLINICS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 GLOBAL AMBULATORY SURGICAL CENTER IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 46 GLOBAL HOMECARE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 47 GLOBAL LABORATORIES IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 48 GLOBAL OTHERS IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 49 GLOBAL STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 50 GLOBAL DIRECT IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 51 GLOBAL RETAIL IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 52 GLOBAL ONLINE IN STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 53 GLOBAL STROKE MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 54 NORTH AMERICA STROKE MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 55 NORTH AMERICA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 56 NORTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 57 NORTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 59 NORTH AMERICA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 60 NORTH AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 61 NORTH AMERICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 62 NORTH AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 63 NORTH AMERICA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 64 NORTH AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 65 NORTH AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 66 NORTH AMERICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 67 NORTH AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 68 NORTH AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 69 NORTH AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 70 NORTH AMERICA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 71 NORTH AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 72 NORTH AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 73 NORTH AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 74 NORTH AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 75 NORTH AMERICA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 76 NORTH AMERICA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 77 NORTH AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 78 NORTH AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 79 NORTH AMERICA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 80 NORTH AMERICA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 81 NORTH AMERICA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 82 NORTH AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 83 NORTH AMERICA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 84 NORTH AMERICA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 85 NORTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 86 U.S. STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 U.S. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 U.S. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 89 U.S. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 90 U.S. STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 91 U.S. MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 92 U.S. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 93 U.S. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 94 U.S. DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 95 U.S. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 96 U.S. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 97 U.S. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 98 U.S. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 99 U.S. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 100 U.S. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 101 U.S. STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 102 U.S. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 103 U.S. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 104 U.S. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 105 U.S. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 106 U.S. ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 107 U.S. PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 108 U.S. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 109 U.S. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 110 U.S. SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 111 U.S. OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 112 U.S. STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 113 U.S. IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 U.S. STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 115 U.S. STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 116 U.S. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 117 CANADA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 CANADA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 CANADA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 CANADA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 121 CANADA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 122 CANADA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 123 CANADA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 124 CANADA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 125 CANADA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 126 CANADA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 127 CANADA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 128 CANADA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 129 CANADA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 130 CANADA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 131 CANADA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 132 CANADA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 133 CANADA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 134 CANADA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 135 CANADA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 136 CANADA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 137 CANADA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 138 CANADA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 139 CANADA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 140 CANADA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 CANADA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 142 CANADA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 143 CANADA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 144 CANADA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 CANADA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 146 CANADA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 147 CANADA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 148 MEXICO STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 MEXICO ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 MEXICO HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 MEXICO STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 152 MEXICO STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 153 MEXICO MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 154 MEXICO BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 155 MEXICO ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 156 MEXICO DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 157 MEXICO CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 158 MEXICO BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 159 MEXICO ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 160 MEXICO ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 161 MEXICO ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 162 MEXICO TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 163 MEXICO STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 164 MEXICO SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 165 MEXICO MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 MEXICO BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 MEXICO MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 168 MEXICO ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 169 MEXICO PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 170 MEXICO MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 171 MEXICO MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 MEXICO SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 173 MEXICO OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 174 MEXICO STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 175 MEXICO IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 MEXICO STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 177 MEXICO STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 178 MEXICO STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 179 EUROPE STROKE MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 180 EUROPE STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 EUROPE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 EUROPE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 EUROPE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 184 EUROPE STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 185 EUROPE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 186 EUROPE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 187 EUROPE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 188 EUROPE DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 189 EUROPE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 190 EUROPE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 191 EUROPE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 192 EUROPE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 193 EUROPE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 194 EUROPE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 195 EUROPE STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 196 EUROPE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 197 EUROPE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 EUROPE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 EUROPE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 200 EUROPE ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 201 EUROPE PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 202 EUROPE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 203 EUROPE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 204 EUROPE SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 205 EUROPE OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 206 EUROPE STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 207 EUROPE IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 208 EUROPE STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 209 EUROPE STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 210 EUROPE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 211 GERMANY STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 GERMANY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 GERMANY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 GERMANY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 215 GERMANY STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 216 GERMANY MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 217 GERMANY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 218 GERMANY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 219 GERMANY DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 220 GERMANY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 221 GERMANY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 222 GERMANY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 223 GERMANY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 224 GERMANY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 225 GERMANY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 226 GERMANY STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 227 GERMANY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 228 GERMANY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 229 GERMANY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 230 GERMANY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 231 GERMANY ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 232 GERMANY PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 233 GERMANY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 234 GERMANY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 235 GERMANY SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 236 GERMANY OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 237 GERMANY STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 238 GERMANY IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 239 GERMANY STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 240 GERMANY STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 241 GERMANY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 242 U.K. STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 243 U.K. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 244 U.K. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 U.K. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 246 U.K. STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 247 U.K. MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 248 U.K. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 249 U.K. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 250 U.K. DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 251 U.K. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 252 U.K. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 253 U.K. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 254 U.K. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 255 U.K. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 256 U.K. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 257 U.K. STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 258 U.K. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 259 U.K. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 260 U.K. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 261 U.K. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 262 U.K. ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 263 U.K. PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 264 U.K. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 265 U.K. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 266 U.K. SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 267 U.K. OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 268 U.K. STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 269 U.K. IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 270 U.K. STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 271 U.K. STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 272 U.K. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 273 FRANCE STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 274 FRANCE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 275 FRANCE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 FRANCE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 277 FRANCE STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 278 FRANCE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 279 FRANCE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 280 FRANCE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 281 FRANCE DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 282 FRANCE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 283 FRANCE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 284 FRANCE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 285 FRANCE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 286 FRANCE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 287 FRANCE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 288 FRANCE STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 289 FRANCE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 290 FRANCE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 291 FRANCE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 292 FRANCE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 293 FRANCE ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 294 FRANCE PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 295 FRANCE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 296 FRANCE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 297 FRANCE SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 298 FRANCE OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 299 FRANCE STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 300 FRANCE IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 301 FRANCE STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 302 FRANCE STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 303 FRANCE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 304 RUSSIA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 305 RUSSIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 306 RUSSIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 307 RUSSIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 308 RUSSIA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 309 RUSSIA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 310 RUSSIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 311 RUSSIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 312 RUSSIA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 313 RUSSIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 314 RUSSIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 315 RUSSIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 316 RUSSIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 317 RUSSIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 318 RUSSIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 319 RUSSIA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 320 RUSSIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 321 RUSSIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 322 RUSSIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 323 RUSSIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 324 RUSSIA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 325 RUSSIA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 326 RUSSIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 327 RUSSIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 328 RUSSIA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 329 RUSSIA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 330 RUSSIA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 331 RUSSIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 332 RUSSIA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 333 RUSSIA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 334 RUSSIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 335 ITALY STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 336 ITALY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 337 ITALY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 338 ITALY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 339 ITALY STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 340 ITALY MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 341 ITALY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 342 ITALY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 343 ITALY DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 344 ITALY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 345 ITALY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 346 ITALY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 347 ITALY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 348 ITALY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 349 ITALY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 350 ITALY STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 351 ITALY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 352 ITALY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 353 ITALY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 354 ITALY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 355 ITALY ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 356 ITALY PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 357 ITALY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 358 ITALY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 359 ITALY SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 360 ITALY OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 361 ITALY STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 362 ITALY IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 363 ITALY STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 364 ITALY STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 365 ITALY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 366 SPAIN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 367 SPAIN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 368 SPAIN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 369 SPAIN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 370 SPAIN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 371 SPAIN MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 372 SPAIN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 373 SPAIN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 374 SPAIN DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 375 SPAIN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 376 SPAIN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 377 SPAIN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 378 SPAIN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 379 SPAIN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 380 SPAIN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 381 SPAIN STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 382 SPAIN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 383 SPAIN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 384 SPAIN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 385 SPAIN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 386 SPAIN ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 387 SPAIN PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 388 SPAIN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 389 SPAIN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 390 SPAIN SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 391 SPAIN OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 392 SPAIN STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 393 SPAIN IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 394 SPAIN STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 395 SPAIN STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 396 SPAIN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 397 TURKEY STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 398 TURKEY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 399 TURKEY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 400 TURKEY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 401 TURKEY STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 402 TURKEY MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 403 TURKEY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 404 TURKEY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 405 TURKEY DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 406 TURKEY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 407 329

TABLE 408 TURKEY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 409 TURKEY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 410 TURKEY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 411 TURKEY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 412 TURKEY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 413 TURKEY STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 414 TURKEY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 415 TURKEY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 416 TURKEY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 417 TURKEY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 418 TURKEY ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 419 TURKEY PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 420 TURKEY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 421 TURKEY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 422 TURKEY SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 423 TURKEY OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 424 TURKEY STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 425 TURKEY IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 426 TURKEY STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 427 TURKEY STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 428 TURKEY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 429 POLAND STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 430 POLAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 431 POLAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 432 POLAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 433 POLAND STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 434 POLAND MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 435 POLAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 436 POLAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 437 POLAND DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 438 POLAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 439 POLAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 440 POLAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 441 POLAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 442 POLAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 443 POLAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 444 POLAND STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 445 POLAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 446 POLAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 447 POLAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 448 POLAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 449 POLAND ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 450 POLAND PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 451 POLAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 452 POLAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 453 POLAND SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 454 POLAND OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 455 POLAND STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 456 POLAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 457 POLAND STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 458 POLAND STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 459 POLAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 460 BELGIUM STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 461 BELGIUM ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 462 BELGIUM HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 463 BELGIUM STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 464 BELGIUM STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 465 BELGIUM MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 466 BELGIUM BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 467 BELGIUM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 468 BELGIUM DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 469 BELGIUM CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 470 BELGIUM BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 471 BELGIUM ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 472 BELGIUM ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 473 BELGIUM ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 474 BELGIUM TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 475 BELGIUM STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 476 BELGIUM SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 477 BELGIUM MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 478 BELGIUM BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 479 BELGIUM MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 480 BELGIUM ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 481 BELGIUM PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 482 BELGIUM MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 483 BELGIUM MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 484 BELGIUM SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 485 BELGIUM OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 486 BELGIUM STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 487 BELGIUM IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 488 BELGIUM STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 489 BELGIUM STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 490 BELGIUM STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 491 NETHERLANDS STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 492 NETHERLANDS ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 493 NETHERLANDS HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 494 NETHERLANDS STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 495 NETHERLANDS STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 496 NETHERLANDS MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 497 NETHERLANDS BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 498 NETHERLANDS ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 499 NETHERLANDS DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 500 NETHERLANDS CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 501 NETHERLANDS BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 502 NETHERLANDS ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 503 NETHERLANDS ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 504 NETHERLANDS ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 505 NETHERLANDS TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 506 NETHERLANDS STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 507 NETHERLANDS SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 508 NETHERLANDS MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 509 NETHERLANDS BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 510 NETHERLANDS MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 511 NETHERLANDS ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 512 NETHERLANDS PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 513 NETHERLANDS MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 514 NETHERLANDS MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 515 NETHERLANDS SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 516 NETHERLANDS OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 517 NETHERLANDS STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 518 NETHERLANDS IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 519 NETHERLANDS STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 520 NETHERLANDS STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 521 NETHERLANDS STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 522 SWITZERLAND STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 523 SWITZERLAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 524 SWITZERLAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 525 SWITZERLAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 526 SWITZERLAND STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 527 SWITZERLAND MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 528 SWITZERLAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 529 SWITZERLAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 530 SWITZERLAND DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 531 SWITZERLAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 532 SWITZERLAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 533 SWITZERLAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 534 SWITZERLAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 535 SWITZERLAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 536 SWITZERLAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 537 SWITZERLAND STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 538 SWITZERLAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 539 SWITZERLAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 540 SWITZERLAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 541 SWITZERLAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 542 SWITZERLAND ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 543 SWITZERLAND PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 544 SWITZERLAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 545 SWITZERLAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 546 SWITZERLAND SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 547 SWITZERLAND OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 548 SWITZERLAND STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 549 SWITZERLAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 550 SWITZERLAND STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 551 SWITZERLAND STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 552 SWITZERLAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 553 DENMARK STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 554 DENMARK ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 555 DENMARK HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 556 DENMARK STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 557 DENMARK STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 558 DENMARK MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 559 DENMARK BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 560 DENMARK ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 561 DENMARK DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 562 DENMARK CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 563 DENMARK BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 564 DENMARK ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 565 DENMARK ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 566 DENMARK ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 567 DENMARK TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 568 DENMARK STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 569 DENMARK SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 570 DENMARK MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 571 DENMARK BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 572 DENMARK MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 573 DENMARK ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 574 DENMARK PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 575 DENMARK MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 576 DENMARK MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 577 DENMARK SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 578 DENMARK OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 579 DENMARK STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 580 DENMARK IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 581 DENMARK STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 582 DENMARK STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 583 DENMARK STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 584 SWEDEN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 585 SWEDEN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 586 SWEDEN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 587 SWEDEN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 588 SWEDEN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 589 SWEDEN MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 590 SWEDEN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 591 SWEDEN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 592 SWEDEN DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 593 SWEDEN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 594 SWEDEN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 595 SWEDEN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 596 SWEDEN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 597 SWEDEN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 598 SWEDEN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 599 SWEDEN STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 600 SWEDEN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 601 SWEDEN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 602 SWEDEN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 603 SWEDEN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 604 SWEDEN ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 605 SWEDEN PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 606 SWEDEN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 607 SWEDEN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 608 SWEDEN SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 609 SWEDEN OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 610 SWEDEN STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 611 SWEDEN IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 612 SWEDEN STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 613 SWEDEN STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 614 SWEDEN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 615 NORWAY STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 616 NORWAY ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 617 NORWAY HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 618 NORWAY STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 619 NORWAY STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 620 NORWAY MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 621 NORWAY BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 622 NORWAY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 623 NORWAY DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 624 NORWAY CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 625 NORWAY BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 626 NORWAY ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 627 NORWAY ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 628 NORWAY ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 629 NORWAY TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 630 NORWAY STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 631 NORWAY SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 632 NORWAY MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 633 NORWAY BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 634 NORWAY MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 635 NORWAY ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 636 NORWAY PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 637 NORWAY MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 638 NORWAY MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 639 NORWAY SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 640 NORWAY OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 641 NORWAY STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 642 NORWAY IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 643 NORWAY STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 644 NORWAY STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 645 NORWAY STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 646 FINLAND STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 647 FINLAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 648 FINLAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 649 FINLAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 650 FINLAND STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 651 FINLAND MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 652 FINLAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 653 FINLAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 654 FINLAND DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 655 FINLAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 656 FINLAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 657 FINLAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 658 FINLAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 659 FINLAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 660 FINLAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 661 FINLAND STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 662 FINLAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 663 FINLAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 664 FINLAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 665 FINLAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 666 FINLAND ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 667 FINLAND PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 668 FINLAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 669 FINLAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 670 FINLAND SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 671 FINLAND OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 672 FINLAND STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 673 FINLAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 674 FINLAND STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 675 FINLAND STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 676 FINLAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 677 REST OF EUROPE STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 678 ASIA-PACIFIC STROKE MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 679 ASIA-PACIFIC STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 680 ASIA-PACIFIC ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 681 ASIA-PACIFIC HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 682 ASIA-PACIFIC STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 683 ASIA-PACIFIC STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 684 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 685 ASIA-PACIFIC BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 686 ASIA-PACIFIC ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 687 ASIA-PACIFIC DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 688 ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 689 ASIA-PACIFIC BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 690 ASIA-PACIFIC ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 691 ASIA-PACIFIC ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 692 ASIA-PACIFIC ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 693 ASIA-PACIFIC TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 694 ASIA-PACIFIC STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 695 ASIA-PACIFIC SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 696 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 697 ASIA-PACIFIC BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 698 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 699 ASIA-PACIFIC ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 700 ASIA-PACIFIC PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 701 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 702 ASIA-PACIFIC MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 703 ASIA-PACIFIC SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 704 ASIA-PACIFIC OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 705 ASIA-PACIFIC STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 706 ASIA-PACIFIC IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 707 ASIA-PACIFIC STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 708 ASIA-PACIFIC STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 709 ASIA-PACIFIC STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 710 CHINA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 711 CHINA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 712 CHINA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 713 CHINA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 714 CHINA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 715 CHINA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 716 CHINA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 717 CHINA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 718 CHINA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 719 CHINA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 720 CHINA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 721 CHINA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 722 CHINA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 723 CHINA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 724 CHINA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 725 CHINA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 726 CHINA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 727 CHINA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 728 CHINA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 729 CHINA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 730 CHINA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 731 CHINA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 732 CHINA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 733 CHINA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 734 CHINA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 735 CHINA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 736 CHINA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 737 CHINA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 738 CHINA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 739 CHINA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 740 CHINA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 741 JAPAN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 742 JAPAN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 743 JAPAN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 744 JAPAN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 745 JAPAN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 746 JAPAN MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 747 JAPAN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 748 JAPAN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 749 JAPAN DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 750 JAPAN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 751 JAPAN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 752 JAPAN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 753 JAPAN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 754 JAPAN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 755 JAPAN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 756 JAPAN STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 757 JAPAN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 758 JAPAN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 759 JAPAN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 760 JAPAN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 761 JAPAN ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 762 JAPAN PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 763 JAPAN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 764 JAPAN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 765 JAPAN SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 766 JAPAN OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 767 JAPAN STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 768 JAPAN IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 769 JAPAN STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 770 JAPAN STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 771 JAPAN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 772 INDIA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 773 INDIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 774 INDIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 775 INDIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 776 INDIA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 777 INDIA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 778 INDIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 779 INDIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 780 INDIA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 781 INDIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 782 INDIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 783 INDIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 784 INDIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 785 INDIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 786 INDIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 787 INDIA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 788 INDIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 789 INDIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 790 INDIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 791 INDIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 792 INDIA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 793 INDIA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 794 INDIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 795 INDIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 796 INDIA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 797 INDIA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 798 INDIA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 799 INDIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 800 INDIA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 801 INDIA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 802 INDIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 803 AUSTRALIA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 804 AUSTRALIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 805 AUSTRALIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 806 AUSTRALIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 807 AUSTRALIA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 808 AUSTRALIA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 809 AUSTRALIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 810 AUSTRALIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 811 AUSTRALIA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 812 AUSTRALIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 813 AUSTRALIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 814 AUSTRALIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 815 AUSTRALIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 816 AUSTRALIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 817 AUSTRALIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 818 AUSTRALIA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 819 AUSTRALIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 820 AUSTRALIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 821 AUSTRALIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 822 AUSTRALIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 823 AUSTRALIA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 824 AUSTRALIA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 825 AUSTRALIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 826 AUSTRALIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 827 AUSTRALIA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 828 AUSTRALIA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 829 AUSTRALIA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 830 AUSTRALIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 831 AUSTRALIA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 832 AUSTRALIA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 833 AUSTRALIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 834 SOUTH KOREA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 835 SOUTH KOREA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 836 SOUTH KOREA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 837 SOUTH KOREA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 838 SOUTH KOREA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 839 SOUTH KOREA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 840 SOUTH KOREA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 841 SOUTH KOREA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 842 SOUTH KOREA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 843 SOUTH KOREA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 844 SOUTH KOREA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 845 SOUTH KOREA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 846 SOUTH KOREA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 847 SOUTH KOREA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 848 SOUTH KOREA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 849 SOUTH KOREA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 850 SOUTH KOREA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 851 SOUTH KOREA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 852 SOUTH KOREA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 853 SOUTH KOREA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 854 SOUTH KOREA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 855 SOUTH KOREA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 856 SOUTH KOREA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 857 SOUTH KOREA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 858 SOUTH KOREA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 859 SOUTH KOREA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 860 SOUTH KOREA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 861 SOUTH KOREA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 862 SOUTH KOREA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 863 SOUTH KOREA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 864 SOUTH KOREA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 865 NEW ZEALAND STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 866 NEW ZEALAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 867 NEW ZEALAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 868 NEW ZEALAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 869 NEW ZEALAND STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 870 NEW ZEALAND MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 871 NEW ZEALAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 872 NEW ZEALAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 873 NEW ZEALAND DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 874 NEW ZEALAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 875 NEW ZEALAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 876 NEW ZEALAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 877 NEW ZEALAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 878 NEW ZEALAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 879 NEW ZEALAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 880 NEW ZEALAND STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 881 NEW ZEALAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 882 NEW ZEALAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 883 NEW ZEALAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 884 NEW ZEALAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 885 NEW ZEALAND ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 886 NEW ZEALAND PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 887 NEW ZEALAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 888 NEW ZEALAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 889 NEW ZEALAND SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 890 NEW ZEALAND OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 891 NEW ZEALAND STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 892 NEW ZEALAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 893 NEW ZEALAND STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 894 NEW ZEALAND STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 895 NEW ZEALAND STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 896 SINGAPORE STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 897 SINGAPORE ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 898 SINGAPORE HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 899 SINGAPORE STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 900 SINGAPORE STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 901 SINGAPORE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 902 SINGAPORE BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 903 SINGAPORE ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 904 SINGAPORE DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 905 SINGAPORE CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 906 SINGAPORE BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 907 SINGAPORE ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 908 SINGAPORE ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 909 SINGAPORE ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 910 SINGAPORE TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 911 SINGAPORE STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 912 SINGAPORE SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 913 SINGAPORE MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 914 SINGAPORE BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 915 SINGAPORE MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 916 SINGAPORE ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 917 SINGAPORE PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 918 SINGAPORE MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 919 SINGAPORE MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 920 SINGAPORE SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 921 SINGAPORE OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 922 SINGAPORE STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 923 SINGAPORE IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 924 SINGAPORE STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 925 SINGAPORE STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 926 SINGAPORE STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 927 THAILAND STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 928 THAILAND ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 929 THAILAND HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 930 THAILAND STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 931 THAILAND STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 932 THAILAND MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 933 THAILAND BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 934 THAILAND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 935 THAILAND DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 936 THAILAND CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 937 THAILAND BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 938 THAILAND ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 939 THAILAND ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 940 THAILAND ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 941 THAILAND TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 942 THAILAND STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 943 THAILAND SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 944 THAILAND MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 945 THAILAND BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 946 THAILAND MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 947 THAILAND ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 948 THAILAND PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 949 THAILAND MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 950 THAILAND MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 951 THAILAND SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 952 THAILAND OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 953 THAILAND STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 954 THAILAND IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 955 THAILAND STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 956 THAILAND STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 957 THAILAND STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 958 PHILIPPINES STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 959 PHILIPPINES ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 960 PHILIPPINES HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 961 PHILIPPINES STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 962 PHILIPPINES STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 963 PHILIPPINES MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 964 PHILIPPINES BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 965 PHILIPPINES ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 966 PHILIPPINES DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 967 PHILIPPINES CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 968 PHILIPPINES BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 969 PHILIPPINES ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 970 PHILIPPINES ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 971 PHILIPPINES ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 972 PHILIPPINES TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 973 PHILIPPINES STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 974 PHILIPPINES SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 975 PHILIPPINES MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 976 PHILIPPINES BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 977 PHILIPPINES MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 978 PHILIPPINES ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 979 PHILIPPINES PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 980 PHILIPPINES MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 981 PHILIPPINES MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 982 PHILIPPINES SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 983 PHILIPPINES OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 984 PHILIPPINES STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 985 PHILIPPINES IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 986 PHILIPPINES STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 987 PHILIPPINES STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 988 PHILIPPINES STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 989 MALAYSIA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 990 MALAYSIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 991 MALAYSIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 992 MALAYSIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 993 MALAYSIA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 994 MALAYSIA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 995 MALAYSIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 996 MALAYSIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 997 MALAYSIA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 998 MALAYSIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 999 MALAYSIA BETA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1000 MALAYSIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1001 MALAYSIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1002 MALAYSIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1003 MALAYSIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1004 MALAYSIA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1005 MALAYSIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1006 MALAYSIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1007 MALAYSIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1008 MALAYSIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1009 MALAYSIA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1010 MALAYSIA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1011 MALAYSIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1012 MALAYSIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1013 MALAYSIA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1014 MALAYSIA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1015 MALAYSIA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1016 MALAYSIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1017 MALAYSIA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1018 MALAYSIA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1019 MALAYSIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1020 INDONESIA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1021 INDONESIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1022 INDONESIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1023 INDONESIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1024 INDONESIA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1025 INDONESIA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1026 INDONESIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1027 INDONESIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1028 INDONESIA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1029 INDONESIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1030 INDONESIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1031 INDONESIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1032 INDONESIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1033 INDONESIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1034 INDONESIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1035 INDONESIA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1036 INDONESIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1037 INDONESIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1038 INDONESIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1039 INDONESIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1040 INDONESIA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1041 INDONESIA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1042 INDONESIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1043 INDONESIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1044 INDONESIA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1045 INDONESIA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1046 INDONESIA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1047 INDONESIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1048 INDONESIA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1049 INDONESIA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1050 INDONESIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1051 VIETNAM STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1052 VIETNAM ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1053 VIETNAM HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1054 VIETNAM STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1055 VIETNAM STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1056 VIETNAM MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1057 VIETNAM BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1058 VIETNAM ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1059 VIETNAM DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1060 VIETNAM CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1061 VIETNAM BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1062 VIETNAM ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1063 VIETNAM ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1064 VIETNAM ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1065 VIETNAM TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1066 VIETNAM STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1067 VIETNAM SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1068 VIETNAM MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1069 VIETNAM BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1070 VIETNAM MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1071 VIETNAM ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1072 VIETNAM PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1073 VIETNAM MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1074 VIETNAM MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1075 VIETNAM SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1076 VIETNAM OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1077 VIETNAM STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1078 VIETNAM IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1079 VIETNAM STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1080 VIETNAM STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1081 VIETNAM STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1082 TAIWAN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1083 TAIWAN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1084 TAIWAN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1085 TAIWAN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1086 TAIWAN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1087 TAIWAN MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1088 TAIWAN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1089 TAIWAN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1090 TAIWAN DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1091 TAIWAN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1092 TAIWAN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1093 TAIWAN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1094 TAIWAN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1095 TAIWAN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1096 TAIWAN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1097 TAIWAN STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1098 TAIWAN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1099 TAIWAN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1100 TAIWAN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1101 TAIWAN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1102 TAIWAN ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1103 TAIWAN PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1104 TAIWAN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1105 TAIWAN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1106 TAIWAN SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1107 TAIWAN OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1108 TAIWAN STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1109 TAIWAN IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1110 TAIWAN STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1111 TAIWAN STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1112 TAIWAN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1113 REST OF ASIA-PACIFIC STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1114 SOUTH AMERICA STROKE MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 1115 SOUTH AMERICA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1116 SOUTH AMERICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1117 SOUTH AMERICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1118 SOUTH AMERICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1119 SOUTH AMERICA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1120 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1121 SOUTH AMERICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1122 SOUTH AMERICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1123 SOUTH AMERICA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1124 SOUTH AMERICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1125 SOUTH AMERICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1126 SOUTH AMERICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1127 SOUTH AMERICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1128 SOUTH AMERICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1129 SOUTH AMERICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1130 SOUTH AMERICA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1131 SOUTH AMERICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1132 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1133 SOUTH AMERICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1134 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1135 SOUTH AMERICA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1136 SOUTH AMERICA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1137 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1138 SOUTH AMERICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1139 SOUTH AMERICA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1140 SOUTH AMERICA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1141 SOUTH AMERICA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1142 SOUTH AMERICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1143 SOUTH AMERICA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1144 SOUTH AMERICA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1145 SOUTH AMERICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1146 BRAZIL STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1147 BRAZIL ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1148 BRAZIL HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1149 BRAZIL STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1150 BRAZIL STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1151 BRAZIL MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1152 BRAZIL BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1153 BRAZIL ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1154 BRAZIL DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1155 BRAZIL CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1156 BRAZIL BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1157 BRAZIL ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1158 BRAZIL ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1159 BRAZIL ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1160 BRAZIL TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1161 BRAZIL STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1162 BRAZIL SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1163 BRAZIL MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1164 BRAZIL BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1165 BRAZIL MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1166 BRAZIL ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1167 BRAZIL PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1168 BRAZIL MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1169 BRAZIL MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1170 BRAZIL SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1171 BRAZIL OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1172 BRAZIL STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1173 BRAZIL IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1174 BRAZIL STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1175 BRAZIL STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1176 BRAZIL STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1177 ARGENTINA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1178 ARGENTINA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1179 ARGENTINA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1180 ARGENTINA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1181 ARGENTINA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1182 ARGENTINA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1183 ARGENTINA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1184 ARGENTINA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1185 ARGENTINA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1186 ARGENTINA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1187 ARGENTINA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1188 ARGENTINA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1189 ARGENTINA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1190 ARGENTINA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1191 ARGENTINA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1192 ARGENTINA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1193 ARGENTINA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1194 ARGENTINA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1195 ARGENTINA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1196 ARGENTINA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1197 ARGENTINA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1198 ARGENTINA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1199 ARGENTINA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1200 ARGENTINA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1201 ARGENTINA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1202 ARGENTINA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1203 ARGENTINA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1204 ARGENTINA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1205 ARGENTINA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1206 ARGENTINA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1207 ARGENTINA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1208 REST OF SOUTH AMERICA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1209 MIDDLE EAST AND AFRICA STROKE MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 1210 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1211 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1212 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1213 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1214 MIDDLE EAST AND AFRICA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1215 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1216 MIDDLE EAST AND AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1217 MIDDLE EAST AND AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1218 MIDDLE EAST AND AFRICA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1219 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1220 MIDDLE EAST AND AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1221 MIDDLE EAST AND AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1222 MIDDLE EAST AND AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1223 MIDDLE EAST AND AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1224 MIDDLE EAST AND AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1225 MIDDLE EAST AND AFRICA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1226 MIDDLE EAST AND AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1227 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1228 MIDDLE EAST AND AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1229 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1230 MIDDLE EAST AND AFRICA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1231 MIDDLE EAST AND AFRICA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1232 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1233 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1234 MIDDLE EAST AND AFRICA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1235 MIDDLE EAST AND AFRICA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1236 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1237 MIDDLE EAST AND AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1238 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1239 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1240 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1241 SAUDI ARABIA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1242 SAUDI ARABIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1243 SAUDI ARABIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1244 SAUDI ARABIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1245 SAUDI ARABIA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1246 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1247 SAUDI ARABIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1248 SAUDI ARABIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1249 SAUDI ARABIA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1250 SAUDI ARABIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1251 SAUDI ARABIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1252 SAUDI ARABIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1253 SAUDI ARABIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1254 SAUDI ARABIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1255 SAUDI ARABIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1256 SAUDI ARABIA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1257 SAUDI ARABIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1258 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1259 SAUDI ARABIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1260 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1261 SAUDI ARABIA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1262 SAUDI ARABIA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1263 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1264 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1265 SAUDI ARABIA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1266 SAUDI ARABIA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1267 SAUDI ARABIA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1268 SAUDI ARABIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1269 SAUDI ARABIA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1270 SAUDI ARABIA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1271 SAUDI ARABIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1272 U.A.E. STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1273 U.A.E. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1274 U.A.E. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1275 U.A.E. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1276 U.A.E. STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1277 U.A.E. MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1278 U.A.E. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1279 U.A.E. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1280 U.A.E. DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1281 U.A.E. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1282 U.A.E. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1283 U.A.E. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1284 U.A.E. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1285 U.A.E. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1286 U.A.E. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1287 U.A.E. STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1288 U.A.E. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1289 U.A.E. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1290 U.A.E. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1291 U.A.E. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1292 U.A.E. ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1293 U.A.E. PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1294 U.A.E. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1295 U.A.E. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1296 U.A.E. SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1297 U.A.E. OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1298 U.A.E. STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1299 U.A.E. IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1300 U.A.E. STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1301 U.A.E. STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1302 U.A.E. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1303 SOUTH AFRICA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1304 SOUTH AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1305 SOUTH AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1306 SOUTH AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1307 SOUTH AFRICA STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1308 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1309 SOUTH AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1310 SOUTH AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1311 SOUTH AFRICA DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1312 SOUTH AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1313 SOUTH AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1314 SOUTH AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1315 SOUTH AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1316 SOUTH AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1317 SOUTH AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1318 SOUTH AFRICA STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1319 SOUTH AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1320 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1321 SOUTH AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1322 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1323 SOUTH AFRICA ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1324 SOUTH AFRICA PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1325 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1326 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1327 SOUTH AFRICA SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1328 SOUTH AFRICA OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1329 SOUTH AFRICA STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1330 SOUTH AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1331 SOUTH AFRICA STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1332 SOUTH AFRICA STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1333 SOUTH AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1334 EGYPT STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1335 EGYPT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1336 EGYPT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1337 EGYPT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1338 EGYPT STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1339 EGYPT MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1340 EGYPT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1341 EGYPT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1342 EGYPT DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1343 EGYPT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1344 EGYPT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1345 EGYPT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1346 EGYPT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1347 EGYPT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1348 EGYPT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1349 EGYPT STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1350 EGYPT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1351 EGYPT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1352 EGYPT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1353 EGYPT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1354 EGYPT ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1355 EGYPT PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1356 EGYPT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1357 EGYPT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1358 EGYPT SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1359 EGYPT OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1360 EGYPT STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1361 EGYPT IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1362 EGYPT STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1363 EGYPT STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1364 EGYPT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1365 QATAR STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1366 QATAR ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1367 QATAR HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1368 QATAR STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1369 QATAR STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1370 QATAR MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1371 QATAR BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1372 QATAR ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1373 QATAR DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1374 QATAR CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1375 QATAR BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1376 QATAR ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1377 QATAR ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1378 QATAR ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1379 QATAR TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1380 QATAR STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1381 QATAR SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1382 QATAR MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1383 QATAR BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND

TABLE 1384 QATAR MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1385 QATAR ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1386 QATAR PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1387 QATAR MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1388 QATAR MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1389 QATAR SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1390 QATAR OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1391 QATAR STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1392 QATAR IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1393 QATAR STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1394 QATAR STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1395 QATAR STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1396 KUWAIT STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1397 KUWAIT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1398 KUWAIT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1399 KUWAIT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1400 KUWAIT STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1401 KUWAIT MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1402 KUWAIT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1403 KUWAIT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1404 KUWAIT DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1405 KUWAIT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1406 KUWAIT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1407 KUWAIT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1408 KUWAIT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1409 KUWAIT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1410 KUWAIT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1411 KUWAIT STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1412 KUWAIT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1413 KUWAIT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1414 KUWAIT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1415 KUWAIT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1416 KUWAIT ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1417 KUWAIT PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1418 KUWAIT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1419 KUWAIT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1420 KUWAIT SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1421 KUWAIT OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1422 KUWAIT STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1423 KUWAIT IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1424 KUWAIT STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1425 KUWAIT STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1426 KUWAIT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1427 OMAN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1428 OMAN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1429 OMAN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1430 OMAN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1431 OMAN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1432 OMAN MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1433 OMAN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1434 OMAN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1435 OMAN DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1436 OMAN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1437 OMAN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1438 OMAN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1439 OMAN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1440 OMAN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1441 OMAN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1442 OMAN STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1443 OMAN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1444 OMAN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1445 OMAN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1446 OMAN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1447 OMAN ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1448 OMAN PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1449 OMAN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1450 OMAN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1451 OMAN SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1452 OMAN OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1453 OMAN STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1454 OMAN IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1455 OMAN STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1456 OMAN STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1457 OMAN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1458 BAHRAIN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1459 BAHRAIN ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1460 BAHRAIN HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1461 BAHRAIN STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1462 BAHRAIN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1463 BAHRAIN MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1464 BAHRAIN BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1465 BAHRAIN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1466 BAHRAIN DIURETICS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1467 BAHRAIN CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1468 BAHRAIN BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1469 BAHRAIN ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1470 BAHRAIN ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1471 BAHRAIN ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1472 BAHRAIN TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1473 BAHRAIN STATINS IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1474 BAHRAIN SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2021-2030 (USD THOUSAND)

TABLE 1475 BAHRAIN MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1476 BAHRAIN BRANDED IN STROKE MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 1477 BAHRAIN MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1478 BAHRAIN ORAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1479 BAHRAIN PARENTERAL IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 1480 BAHRAIN MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND)

TABLE 1481 BAHRAIN MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1482 BAHRAIN SURGERY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1483 BAHRAIN OTHER THERAPY IN STROKE MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND)

TABLE 1484 BAHRAIN STROKE MARKET, BY DIAGNOSIS, 2021-2030 (USD THOUSAND)

TABLE 1485 BAHRAIN IMAGING TEST IN STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 1486 BAHRAIN STROKE MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 1487 BAHRAIN STROKE MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 1488 BAHRAIN STROKE MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 1489 REST OF MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The stroke market size will be worth USD 52,232,195.85 thousand by 2030.
The growth rate of the stroke market is 7.5% in the forecast period by 2030.
Type, diagnostic type, treatment type, therapeutic type, route of administration, mode of purchase, and end type are the factors on which the stroke market research is based.
The increasing prevalence of stroke, advancements in treatment options, and technological advancements are the growth drivers of the stroke market.
Siemens announced the launch of their new Somatom X. ceed1, a new high-resolution, high-speed CT (computed tomography) scanner which is engineered specifically for the most challenging clinical areas and Koninklijke Philips N.V. announced its strategic partnership with Ibex Medical Analytics to jointly promote its digital pathology are the latest developments in the stroke market.

BROWSE RELATED REPORTS

Global Ischemic Cerebral Stroke Market - Industry Trends and Forecast to 2029
Global Telestroke Market – Industry Trends and Forecast to 2029
U.S. Telestroke Market – Industry Trends and Forecast to 2031

BROWSE RELATED Blogs

Future Directions: Potential Breakthroughs and Novel Approaches in Ischemic Cerebral Stroke Care
Telestroke Market: Advancing Stroke Care through Remote Diagnosis and Treatment Technologies
Navigating the Volatile Stroke Market: Trends, Insights, and Strategies for Success in Healthcare Investment

BROWSE RELATED Press Release

Optimizing Telestroke Access: Navigating Distribution Channels for Remote Stroke Care Solutions
Increasing Number of Patients with Hypertension and Coronary Heart Diseases is expected to act as a Driver for the growth of the Global Stroke Market
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future